- Exchange: -
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Medicis Pharmaceutical Corp
MRX:US
Acquired
More on MRX
News for Medicis Pharmaceutical Corp (MRX)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Actavis Gaining More From Purchase Than Sale: Real M&A
- Actavis Said to Have Spurned $15 Billion Offer From Mylan
- Actavis Says It’s in Early Talks to Buy Warner Chilcott
- Actavis Seen Selling for Higher Valuation: Real M&A
- Serbia Extends Galenika Tender Again Giving Valeant More Time
- Valeant Merger Talks With Actavis Said to Stall on Price
- Canada Stocks Rise as Commodities Rally Amid Stimulus Optimism
- Valeant in Talks With Actavis on Merger of Generic Drug Makers
- Serbia’s Drugmaker Galenika Cuts Net Loss 58% to $65.8 Million
- Iamgold Dives as Valeant Soars in Index Split
- Serbia Picks Valeant as Sole Bidder for Galenika
- Merz Declines to Raise Bid for Obagi, Yielding to Valeant
- Obagi Bidding War Seen Pushing Premium to 99%: Real M&A
- Valeant Raises Obagi Offer to $417 Million After Merz Bid
- Valeant Raises Offer for Obagi Medical After Merz Bid
- Retrophin Names Marc L. Panoff as Chief Financial Officer Published May 08, 2013
- Hyperion Therapeutics Exercises Option to Acquire Rights to BUPHENYL(R) and AMMONUL(R) Published May 02, 2013
- Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results Published May 02, 2013
- Lundbeck’s Brintellix Is More Effective in Higher Dose in Study
- SAC Says Cooperation With U.S. No Longer ‘Unconditional’
- Credit Swaps in U.S. Fall as Leading Indicators, Sentiment Rise
- Puma Biotech Gains After Rival Drug Data Show No Threat
- J&J Will Stop Sales of Metal-on-Metal Hip Replacements
- Sanofi, French Government at Odds Over Fate of Research Site
- Expected Earnings Growth for Industries in Stoxx 600
- Petrobras, Merck Lead $54 Billion of Company Bond Sales in U.S.
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
- Lilly, ThyssenKrupp, Adidas, AMD: Intellectual Property
- Glaxo Sees Emerging Market Price Cuts Driving Drug Volume Growth
- Final Soccer World Cup Sponsor to Spend $50 Million in 15 Months
- Japan REITs Favored, May Gain 25%, Freeze Says
- Billionaire Frost Props Up Prolor Bid With Stock Buys
- Bristol-Myers Drug Cocktail Stymies Melanoma Tumors
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page